CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 81 enrolled
Drug / intervention
enzastaurin +3 moredrug
Likely dose
enzastaurin 1125 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00586508
NCT00586508Phase 2Completed
CompareCT.gov

A Phase II Trial of Enzastaurin in Combination With Bevacizumab in Adults With Recurrent Malignant Gliomas

Eli Lilly and Company·interventional·Posted Jan 4, 2008·Updated Sep 24, 2020

In Brief

A Phase 2 clinical trial evaluating enzastaurin, bevacizumab, and 2 other interventions for Recurrent Glioblastoma. Completed, enrolled 81 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Glioblastoma
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 4, 2008
Enrollment StartNov 1, 2007
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 18.5 years ago

Interventions

enzastaurindrug

1125 milligrams (mg) loading dose then 500 or 875 mg, orally, daily, 4-week cycles with participants evaluated after each cycle. The dose difference is for participants who are on enzyme-inducing antiepileptic drugs (EIAED) versus non-enzyme inducing antiepileptic drugs (NEIAED).

bevacizumabdrug

10 milligrams per kilogram (mg/kg), intravenously (IV), every 2 weeks, participants are evaluated after each cycle (4-week cycles).

Enzyme-inducing antiepileptic drugs (EIAED)drug

Administered orally

Non-enzyme inducing antiepileptic drugs (NEIAED)drug

Administered orally